Pharmacological treatment of severe, therapy-resistant asthma in children: What can we learn from where?

  • A. B
  • S. P
  • G. H
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

There is a lack of high-quality evidence on what treatment should be used in children with properly characterised severe, therapy-resistant asthma. Data have to be largely extrapolated from trials in children with mild asthma, and adults with severe asthma. Therapeutic options can be divided into medications used in lower doses for children with less severe asthma, and those used in other paediatric diseases but not for asthma (for example, methotrexate). In the first category are high-dose inhaled corticosteroids (ICS) (≤2,000 μg·day-1 fluticasone equivalent), oral prednisolone, the anti-immunoglobulin (Ig)E antibody omalizumab, high-dose long-acting β2-agonists, low-dose oral theophylline and intramuscular triamcinolone. If peripheral airway inflammation is thought to be a problem, the use of fine-particle ICS or low-dose oral corticosteroids may be considered. More experimental therapies include oral macrolides, cyclosporin, cytotoxic drugs such as methotrexate and azathioprine, gold salts, intravenous infusions of Ig, subcutaneous β2-agonist treatment and, in those sensitised to fungi, oral antifungal therapy with itraconazole or voriconazole. Those with recurrent severe exacerbations, particularly in the context of good baseline asthma control, are particularly difficult to treat; baseline control and lung function must be optimised with the lowest possible dose of ICS, and allergen triggers and exposures minimised. The use of high-dose ICS, leukotriene receptor antagonists or both at the time of exacerbations can be considered. There is no evidence regarding which therapeutic option to recommend. Better evidence is required for all these treatment options, underscoring the need for the international and co-ordinated approach which we have previously advocated. Copyright©ERS 2011.

Author-supplied keywords

  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae
  • allergic asthma
  • aseptic meningitis
  • asthma
  • azathioprine
  • beclometasone
  • beta 2 adrenergic receptor stimulating agent
  • bronchiectasis
  • bronchiolitis
  • budesonide plus formoterol
  • child
  • clarithromycin
  • corticosteroid
  • cyclosporin
  • cystic fibrosis
  • diffuse panbronchiolitis
  • disease exacerbation
  • disease severity
  • drug blood level
  • drug clearance
  • drug dose increase
  • drug dose reduction
  • drug efficacy
  • drug half life
  • drug intermittent therapy
  • drug megadose
  • drug safety
  • eosinophilia
  • erythromycin
  • fluticasone propionate
  • forced expiratory volume
  • gold salt
  • human
  • hypoglycemia
  • hypokalemia
  • immunoglobulin
  • itraconazole
  • leukotriene receptor blocking agent
  • liver function
  • low drug dose
  • macrolide
  • methotrexate
  • methylprednisolone
  • montelukast
  • myositis
  • omalizumab
  • placebo
  • prednisolone
  • priority journal
  • respiratory tract inflammation
  • review
  • roxithromycin
  • side effect
  • symbicort
  • telithromycin
  • terbutaline
  • theophylline
  • triamcinolone
  • troleandomycin
  • unspecified side effect
  • voriconazole

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Bush Barbato A.

  • Pedersen S.

  • Hedlin G.

  • Baraldi E.

  • Bush Barbato A.

  • De Benedictis F.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free